These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 27244099)
1. Frequency of telomerase reverse transcripter promoter mutations in desmoplastic melanoma subtypes: analyses of 76 cases. Yang S; Leone D; Frydenlund N; Hoang M; Deng A; Hernandez-Perez M; Biswas A; Singh R; Yaar R; Mahalingam M Melanoma Res; 2016 Aug; 26(4):361-6. PubMed ID: 27244099 [TBL] [Abstract][Full Text] [Related]
2. Neurofibromin protein loss in desmoplastic melanoma subtypes: implicating NF1 allelic loss as a distinct genetic driver? Kadokura A; Frydenlund N; Leone DA; Yang S; Hoang MP; Deng A; Hernandez-Perez M; Biswas A; Singh R; Yaar R; Mahalingam M Hum Pathol; 2016 Jul; 53():82-90. PubMed ID: 26980030 [TBL] [Abstract][Full Text] [Related]
4. Differing biologic behaviors of desmoplastic melanoma subtypes: Insights based on histopathologic, immunohistochemical, and genetic analyses. Yang K; Mahalingam M J Am Acad Dermatol; 2020 Aug; 83(2):523-531. PubMed ID: 32068045 [TBL] [Abstract][Full Text] [Related]
5. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Macerola E; Loggini B; Giannini R; Garavello G; Giordano M; Proietti A; Niccoli C; Basolo F; Fontanini G Virchows Arch; 2015 Aug; 467(2):177-84. PubMed ID: 26055532 [TBL] [Abstract][Full Text] [Related]
10. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions. Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM; Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205 [TBL] [Abstract][Full Text] [Related]
12. BRAF and epithelial-mesenchymal transition in primary cutaneous melanoma: a role for Snail and E-cadherin? Mitchell B; Leone DA; Feller JK; Yang S; Mahalingam M Hum Pathol; 2016 Jun; 52():19-27. PubMed ID: 26980024 [TBL] [Abstract][Full Text] [Related]
13. TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases. Jangard M; Zebary A; Ragnarsson-Olding B; Hansson J Melanoma Res; 2015 Jun; 25(3):185-8. PubMed ID: 25746036 [TBL] [Abstract][Full Text] [Related]
14. Telomerase reverse transcriptase promoter mutations and solar elastosis in cutaneous melanoma. Lade-Keller J; Yuusufi S; Riber-Hansen R; Steiniche T; Stougaard M Melanoma Res; 2018 Oct; 28(5):398-409. PubMed ID: 29570169 [TBL] [Abstract][Full Text] [Related]
15. Analysis of SDHD promoter mutations in various types of melanoma. Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518 [TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutation subtypes and survival in stage I and II melanoma patients. Andrés-Lencina JJ; Rachakonda S; García-Casado Z; Srinivas N; Skorokhod A; Requena C; Soriano V; Kumar R; Nagore E Int J Cancer; 2019 Mar; 144(5):1027-1036. PubMed ID: 30070694 [TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites. Cheng KA; Kurtis B; Babayeva S; Zhuge J; Tantchou I; Cai D; Lafaro RJ; Fallon JT; Zhong M Ann Diagn Pathol; 2015 Jun; 19(3):146-8. PubMed ID: 25862495 [TBL] [Abstract][Full Text] [Related]
18. Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients. Roh MR; Park KH; Chung KY; Shin SJ; Rha SY; Tsao H Am J Cancer Res; 2017; 7(1):134-138. PubMed ID: 28123854 [TBL] [Abstract][Full Text] [Related]
19. Classifying Melanoma by TERT Promoter Mutational Status. Shaughnessy M; Njauw CN; Artomov M; Tsao H J Invest Dermatol; 2020 Feb; 140(2):390-394.e1. PubMed ID: 31425705 [TBL] [Abstract][Full Text] [Related]